










wherein:

R is independently selected from the group consisting of




or a pharmaceutically acceptable salt or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier.

5. (Once amended) A method for the treatment of hepatitis C virus (HCV) infection comprising administering an effective amount of a compound selected from the group consisting of formulas [I] – [IV] below and mixtures of two or more thereof:







wherein:

R is independently selected from the group consisting of



or a pharmaceutically acceptable salt or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier.


9. (Once amended) A method for the treatment of hepatitis D virus (HDV) infection comprising administering an effective amount of a compound selected from the group consisting of formulas [I] – [IV] below and mixtures of two or more thereof:



A³
cont'd





wherein:

R is independently selected from the group consisting of



or a pharmaceutically acceptable salt or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier.






17. (Once amended) A pharmaceutical composition for the treatment of HBV comprising a combination of an effective amount of an anti-HBV agent and an effective amount of a compound selected from the group consisting of formulas [I] – [IV] below and mixtures of two or more thereof:



A4
contd





wherein:

R is independently selected from the group consisting of



or a pharmaceutically acceptable salt or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier.


19. (Once amended) A pharmaceutical composition for the treatment of HCV comprising an anti-HCV agent and an effective amount of a compound selected from the group consisting of formulas [I] – [IV] below and mixtures of two or more thereof:



wherein:





AS
cont'd

R is independently selected from the group consisting of



or a pharmaceutically acceptable salt or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier.


21. (Once amended) A pharmaceutical composition for the treatment of HDV comprising an anti-HDV agent and an effective amount of a compound selected from the group consisting of formulas [I] – [IV] below and mixtures of two or more thereof:



Alc
cont'd

wherein:

R is independently selected from the group consisting of



or a pharmaceutically acceptable salt or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier.

33. (new) The method of Claim 1, wherein the compound is Formula I.
34. (new) The method of Claim 1, wherein the compound is Formula II,
35. (new) The method of Claim 1, wherein the compound is Formula III.
36. (new) The method of Claim 1, wherein the compound is Formula IV.
37. (new) The method of Claim 33, wherein R is H.
38. (new) The method of Claim 34, wherein R is H.

39. (new) (new) The method of Claim 35, wherein R is H.
40. (new) (new) The method of Claim 36, wherein R is H.
41. (new) The method of Claim 5, wherein the compound is Formula I.
42. (new) The method of Claim 5, wherein the compound is Formula II,
43. (new) The method of Claim 5, wherein the compound is Formula III.
44. (new) The method of Claim 5, wherein the compound is Formula IV.
45. (new) The method of Claim 41, wherein R is H.
46. (new) The method of Claim 42, wherein R is H.
47. (new) The method of Claim 43, wherein R is H.
48. (new) The method of Claim 44, wherein R is H.
49. (new) The method of Claim 9, wherein the compound is Formula I.
50. (new) The method of Claim 9, wherein the compound is Formula II,
51. (new) The method of Claim 9, wherein the compound is Formula III.
52. (new) The method of Claim 9, wherein the compound is Formula IV.
53. (new) The method of Claim 49, wherein R is H.
54. (new) The method of Claim 50, wherein R is H.
55. (new) The method of Claim 51, wherein R is H.
56. (new) The method of Claim 52, wherein R is H.
57. (new) The pharmaceutical composition of Claim 17, wherein the compound is Formula I.
58. (new) The pharmaceutical composition of Claim 17, wherein the compound is Formula II,
59. (new) The pharmaceutical composition of Claim 17, wherein the compound is Formula III.
60. (new) The pharmaceutical composition of Claim 17, wherein the compound is Formula IV.
61. (new) The pharmaceutical composition of Claim 57, wherein R is H.
62. (new) The pharmaceutical composition of Claim 58, wherein R is H.
63. (new) The pharmaceutical composition of Claim 59, wherein R is H.
64. (new) The pharmaceutical composition of Claim 60, wherein R is H.
65. (new) The pharmaceutical composition of Claim 19, wherein the compound is Formula I.

A7
contd